FGF19 Gene Overexpression clinical trials at UCSF
1 research study open to eligible people
FGF19 gene overexpression means the body makes too much FGF19 protein. UCSF is running early phase studies to check safety of a therapy for liver and other solid tumors with FGF19 pathway alterations. The trials monitor side effects and tumor activity.
Showing trials for
Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
open to eligible people ages 18 years and up
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
San Francisco, California and other locations
Last updated: